Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors.

Malvacio I, Cuzzolin A, Sturlese M, Vera DMA, Moyano EL, Moro S.

J Enzyme Inhib Med Chem. 2017 Dec;33(1):171-183. doi: 10.1080/14756366.2017.1404592.

PMID:
29210298
2.

AquaMMapS: An Alternative Tool to Monitor the Role of Water Molecules During Protein-Ligand Association.

Cuzzolin A, Deganutti G, Salmaso V, Sturlese M, Moro S.

ChemMedChem. 2018 Mar 20;13(6):522-531. doi: 10.1002/cmdc.201700564. Epub 2018 Jan 25.

PMID:
29193885
3.

Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity.

Carta D, Bortolozzi R, Hamel E, Basso G, Moro S, Viola G, Ferlin MG.

J Med Chem. 2015 Oct 22;58(20):7991-8010. doi: 10.1021/acs.jmedchem.5b00805. Epub 2015 Oct 7.

4.

(1)H, (13)C, and (15)N backbone resonance assignments of the full-length 40 kDa S. acidocaldarius Y-family DNA polymerase, dinB homolog.

Moro SL, Cocco MJ.

Biomol NMR Assign. 2015 Oct;9(2):441-5. doi: 10.1007/s12104-015-9626-y. Epub 2015 Jul 8.

PMID:
26154586
5.

DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations.

Cuzzolin A, Sturlese M, Malvacio I, Ciancetta A, Moro S.

Molecules. 2015 May 29;20(6):9977-93. doi: 10.3390/molecules20069977.

6.

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, Pillon M, Moro S, Basso G, Rosolen A, Bonvini P.

PLoS One. 2015 Apr 13;10(4):e0121378. doi: 10.1371/journal.pone.0121378. eCollection 2015.

7.

Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.

Frezzato F, Trimarco V, Martini V, Gattazzo C, Ave E, Visentin A, Cabrelle A, Olivieri V, Zambello R, Facco M, Zonta F, Cristiani A, Brunati AM, Moro S, Semenzato G, Trentin L.

Br J Haematol. 2014 Jun;165(5):659-72. doi: 10.1111/bjh.12815. Epub 2014 Mar 7.

PMID:
24606526
8.

Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.

Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, Pennelli G, Casal Ide E, Pelizzo MR, Mantero F, Moro S, Mian C.

Thyroid. 2014 May;24(5):809-19. doi: 10.1089/thy.2013.0403. Epub 2014 Jan 23.

PMID:
24295088
9.

Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer.

Barollo S, Pezzani R, Cristiani A, Bertazza L, Rubin B, Bulfone A, Pelizzo MR, Torresan F, Mantero F, Pennelli G, Moro S, Mian C.

Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):546-50. doi: 10.1055/s-0033-1351299. Epub 2013 Aug 9.

PMID:
23934677
10.

Kinase CK2 inhibition: an update.

Cozza G, Pinna LA, Moro S.

Curr Med Chem. 2013;20(5):671-93. Review.

PMID:
23210774
11.

Protein kinase CK2 inhibitors: a patent review.

Cozza G, Pinna LA, Moro S.

Expert Opin Ther Pat. 2012 Sep;22(9):1081-97. doi: 10.1517/13543776.2012.717615. Review.

PMID:
22908959
12.

Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.

Cozza G, Gianoncelli A, Bonvini P, Zorzi E, Pasquale R, Rosolen A, Pinna LA, Meggio F, Zagotto G, Moro S.

ChemMedChem. 2011 Dec 9;6(12):2273-86. doi: 10.1002/cmdc.201100338. Epub 2011 Oct 4.

PMID:
21972104
13.

MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells.

Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, Castagliuolo I, Ferlin MG, Basso G.

Biochem Pharmacol. 2012 Jan 1;83(1):16-26. doi: 10.1016/j.bcp.2011.09.017. Epub 2011 Sep 22.

14.

The dark side of protein kinase CK2 inhibition.

Cozza G, Meggio F, Moro S.

Curr Med Chem. 2011;18(19):2867-84. Review.

PMID:
21651492
15.

The role of the N-terminal domain in the regulation of the "constitutively active" conformation of protein kinase CK2α: insight from a molecular dynamics investigation.

Cristiani A, Costa G, Cozza G, Meggio F, Scapozza L, Moro S.

ChemMedChem. 2011 Jul 4;6(7):1207-16. doi: 10.1002/cmdc.201100046. Epub 2011 May 17.

PMID:
21591262
16.

ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents.

Cozza G, Bortolato A, Menta E, Cavalletti E, Spinelli S, Moro S.

Anticancer Agents Med Chem. 2009 Sep;9(7):778-86. Review.

PMID:
19799530
17.

How druggable is protein kinase CK2?

Cozza G, Bortolato A, Moro S.

Med Res Rev. 2010 May;30(3):419-62. doi: 10.1002/med.20164. Review.

PMID:
19526464
18.

A novel splicing variant encoding putative catalytic alpha subunit of maize protein kinase CK2.

Lebska M, Szczegielniak J, Dobrowolska G, Cozza G, Moro S, Muszyńska G.

Physiol Plant. 2009 Jul;136(3):251-63. doi: 10.1111/j.1399-3054.2009.01238.x. Epub 2009 May 22.

PMID:
19470094
19.

Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.

Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, di Maira G, Gianoncelli A, Pagano MA, Sarno S, Ruzzene M, Battistutta R, Meggio F, Moro S, Zagotto G, Pinna LA.

Biochem J. 2009 Jul 15;421(3):387-95. doi: 10.1042/BJ20090069.

PMID:
19432557
20.

Supplemental Content

Loading ...
Support Center